Investors & Media

Transformative science, targeted medicines

Blueprint Medicines is a fully integrated global biopharmaceutical company that invents life-changing medicines across two strategic focus areas of allergy/inflammation and oncology/hematology. Our approach combines deep scientific expertise, modality-agnostic drug discovery capabilities, and a proven track record of R&D success. Currently, we are commercializing our approved medicine AYVAKIT/AYVAKYT® (avapritinib) in the U.S. and Europe, as well as in other regions of the world through partnerships.

SEC Filings

SEC Filings

Search
Filing date Form Description View
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-005222.pdf
0001415889-22-005222.rtf
0001415889-22-005222.xls
SC 13G

A statement of beneficial ownership of common stock by certain persons

 View HTML
0000315066-22-001575.pdf
0000315066-22-001575.rtf
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-055023.pdf
0001104659-22-055023.rtf
0001104659-22-055023.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
10-Q

Quarterly report which provides a continuing view of a company's financial position

 View HTML
0001558370-22-006801.pdf
0001558370-22-006801.rtf
0001558370-22-006801.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-052847.pdf
0001104659-22-052847.rtf
0001104659-22-052847.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

 View HTML
0001558370-22-006381.pdf
0001558370-22-006381.rtf
0001558370-22-006381.xls
DEFA14A

Additional proxy soliciting materials - definitive

 View HTML
0001558370-22-006383.pdf
0001558370-22-006383.rtf
0001558370-22-006383.xls
3

Initial filing by director officer or owner of more than ten percent.

 View HTML
0001415889-22-004061.pdf
0001415889-22-004061.rtf
0001415889-22-004061.xls
8-K

Report of unscheduled material events or corporate event

 View HTML
0001104659-22-044050.pdf
0001104659-22-044050.rtf
0001104659-22-044050.xls
EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA
4

Statement of changes in beneficial ownership of securities

 View HTML
0001415889-22-003957.pdf
0001415889-22-003957.rtf
0001415889-22-003957.xls